Seribantumab (Merrimack Pharmaceuticals) is a monoclonal antibody directed against human epidermal growth factor receptor 3 (HER3), also known as ErbB3. HER3 is a member of the epidermal growth factor receptor family of kinases and is commonly overexpressed in solid tumors, including lung cancer. In particular, seribantumab targets heregulin (HRG)-positive cancer cells, which are characterized by their ability to escape the effects of targeted, cytotoxic, and anti-endocrine therapies. Seribantumab blocks the HRG/HER3 signaling axis in order to make these cells accessible to the effects of these therapies.
4 Drug Overview
5 Product Profiles
5 seribantumab : Non-small cell lung cancer (NSCLC)
LIST OF FIGURES
8 Figure 1: Seribantumab for non-small cell lung cancer – SWOT analysis
9 Figure 2: Datamonitor Healthcare’s drug assessment summary for seribantumab in non-small cell lung cancer
10 Figure 3: Datamonitor Healthcare’s drug assessment summary for seribantumab in non-small cell lung cancer
12 Figure 4: Seribantumab sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
6 Table 1: Seribantumab drug profile
7 Table 2: Seribantumab Phase III trials in non-small cell lung cancer
7 Table 3: Seribantumab early-phase data in non-small cell lung cancer
13 Table 4: Seribantumab sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
15 Table 5: Seribantumab patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.